Clinical Pharmacology of Substance Use Disorder

Magí Farré Albaladejo

The objectives of the group are to study the acute and chronic pharmacological and tòxic  effects caused by substance abuse in humans.  The members of the group are mostly physicians at the Germans Trias i Pujol Hospital responsible for daily patient care."

View publications for the group

Líneas de investigación

The three mains lines of research are:

  • Evaluation of the acute effects of new psychoactive substances (synthetic cathinones such as mephedrone, synthetic cannabinoids, phyenylamines like 2-CB, methylone and alpha-PVP)
  • Evaluation of the acute and chronic effects of binge alcohol consumption in young people and its combination with other substances (cannabis, energy drinks)
  • Evaluation of the effects of cannabis and its components, including its possible therapeutic use  (medicinal cannabis)

In all three lines, this evaluation includes pharmacodynamics, pharmacokinetics and metabolic aspects and biomarkers associated with consumption.

Members of the Group

The members of the group are research and clinical staff of the Addiction Unit within the Internal Medicine Service of the Germans Trias i Pujol Hospital, who are all affiliated to the IGTP.

Magí Farré Albaladejo(ELIMINAR), Group Leader and PI
Clara Pérez Mañá(ELIMINAR), PI
Esther Papaseit Fontanet(ELIMINAR), PI
Lourdes Poyatos Blanco(ELIMINAR)
Ana Pilar Pérez Acevedo(ELIMINAR)
Olga Hladun Alvaro(ELIMINAR)
Soraya Martin Sánchez(ELIMINAR)
Cristina Rubio Esteve

Ongoing Projects

Nuevas sustancias psicoactivas: evaluación del potencial de abuso y farmacología humana de un cannabinoide sintético

Code: PI14/00715
Principlal Investigator: Magí Farré                                                                                             
Start Date: 2015
End Date: 2019


Biomarcadores del consumo abusivo de alcohol y cannabis asociados en adultos y menores

Code:  2015I054
PI: Esther Papaseit
Start date: 2016
End date: 2019


Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos (SCReN)

Code: PT17/0016/0017
PI: Magí Farré
Start date: 2018
End date: 2020


Contrato Joan Rodés

Code: JR16/00020
PI: Magí Farré
Start date: 2017
End date: 2020


Plan Nacional sobre Drogas: Biomarcadores de daño agudo y exposición al alcohol tras consumo en atracón-binge drinking en jóvenes y menores

Code: 2016I024
PI: Magí Farré
Start date: 2017
End date: 2019


Potencial de abuso y farmacología humana de nuevas catinonas sintéticas

Code: PI17/01962
PI: Magí Farré
Start date: 2017
End date: 2019


Analysis, knowledge dissemination, JUstice implementation and Special Testing of novel Synthetic Opioids (JUSTSO)

Code: 806996 - JUSTSO - JUST-2017-AG-DRUG
PI: Magí Farré
Start date: 2018
End date: 2020


Complicacions mèdiques i farmacología clínica del trastorn per ús de substàncies

Code: 2017 SGR 316
PI: Robert Muga
Start date: 2018
End date: 2019


Contratos Predoctorales de Formación en investigación en salud (PFIS)

Code: FI18/00179
PI: Magí Farré
Start date: 2019
End date: 2021


Combinación de alcohol y bebidas energéticas en patrón de atracón-binge drinking: Efectos agudos y diferencias de género

Code: 2018I037
PI: Clara Pérez
Start date: 2019
End date: 2021


Més informació

Contacto

Magí Farré Albaladejo

(+34) 93 4978865

mfarre.germanstrias(ELIMINAR)@gencat.cat